Larvol Delta - Risk-factors-affecting-the-clinical-course-of-COVID19-in-patients-with-lymphoid-malignancies-in-the-Omicron-subvariants-era--a160realworld-analysis-by-the-Polish-Adult-Lukemia-Study-Group

Paxlovid (nirmatrelvir/ritonavir) - Pfizer

Lagevrio (molnupiravir) - Ridgeback Biotherap, Merck (MSD)

remdesivir - Generic mfg.

http://www.ncbi.nlm.nih.gov/pubmed/42374683

Agnieszka Szymczyk; Antonina Dytfeld; Iwona Hus

Jul 1, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next